PHR1362
酢酸カルシウム
Pharmaceutical Secondary Standard; Certified Reference Material
別名:
Calcium acetate
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
(CH3CO2)2Ca
CAS番号:
分子量:
158.17
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-540-9
MDL number:
InChI key
VSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
SMILES string
CC(=O)O[Ca]OC(C)=O
grade
certified reference material, pharmaceutical secondary standard
agency
traceable to USP 1086334
API family
calcium acetate
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
impurities
~1% Acetic acid
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
Application
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
General description
Calcium Acetate belongs to the group of calcium salts, widely used as phosphorus binders in patients with chronic renal failure.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Other Notes
To see an example of a Certificate of Analysis for this material enter LRAA1466 in the slot below. This is an example certificate only and may not be the lot that you receive.
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
PHR1362-5G-PW: + PHR1362-5G:
jan
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Daniel T Grima et al.
Current medical research and opinion, 29(2), 109-115 (2012-12-12)
The avoidance of hospitalizations and the maintenance of in-center dialysis sessions in patients receiving dialysis for end-stage renal disease (ESRD) have obvious benefits to patients, dialysis providers and payers. Benefits include better continuity of care, better patient outcomes, improved quality
Leonardo V Riella et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 57(4), 641-645 (2011-02-22)
Hypophosphatemia is a common complication after kidney transplant, affecting >90% of patients. However, no specific recommendations for phosphate repletion exist for transplant recipients. We report a case of a 70-year-old highly sensitized woman with end-stage renal disease caused by diabetic
Meagan L Harless et al.
Environmental toxicology and chemistry, 30(7), 1637-1641 (2011-04-08)
Widespread and intensive application of road deicers, primarily road salt (NaCl), in North America threatens water quality and the health of freshwater ecosystems. Intensive use of NaCl can be harmful to sensitive members of freshwater ecosystems such as amphibians. Detection
Alastair J Hutchison et al.
Nature reviews. Nephrology, 7(10), 578-589 (2011-09-07)
The ideal serum level of phosphate in patients on dialysis, and the benefits of controlling levels of phosphate in serum remain unclear despite observational studies that associate phosphate levels with mortality. In the absence of robust data from trials, current
Rodrigo B de Oliveira et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28(10), 2510-2517 (2013-08-27)
Mineral bone disorder (MBD) is an early complication of chronic kidney disease (CKD), with complex interactions in the bone-kidney-energy axis. These events lead to impaired bone remodelling, which in turn is associated with cardiovascular disease. Recently, we reported on a
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）